Latest news

Latest publications

  • Rouviere B, Le Dantec C, Foulquier N, Cornec D, Pers JO, De Moreuil C, Hillion S. Hétérogénéité des mécanismes auto-immuns impliques dans la sclérodermie systémique. La Revue de Médecine Interne. 2023;44:A383-A4. doi: 10.1016/j.revmed.2023.10.094


  • Mariniello M, Schiano G, Yoshifuji A, Gillion V, Sayer JA, Jouret F, Genkyst Study Group, Le Meur Y, Cornec-Le Gall E, Olinger EG, Devuyst O, Uromodulin Processing in DNAJB11-kidney Disease, Kidney International (2023), doi: 10.1016/j.kint.2023.11.008


  • Saraux A, Le Henaff C, Dernis E, Carvajal-Alegria G, Tison A, Quere B, Petit H, Felten R, Jousse-Joulin S, Guellec D, Marhadour T, Kervarrec P, Cornec D, Querellou S, Nowak E, Souki A, Devauchelle-Pensec V. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. The Lancet Rheumatology. 2023;5(12):e728-e35. doi: 10.1016/S2665-9913(23)00246-1


  • Toufiq M, Rinchai D, Bettacchioli E, Kabeer BSA, Khan T, Subba B, White O, Yurieva M, George J, Jourde-Chiche N, Chiche L, Palucka K, Chaussabel D. Harnessing large language models (LLMs) for candidate gene prioritization and selection. J Transl Med. 2023 Oct 16;21(1):728. doi: 10.1186/s12967-023-04576-8.


  • Preprint: Desvaux EHemon P, Soret P, Le Dantec CChatzis LCornec D, Devauchelle-Pensec V and Study Group, PRECISESADS Clinical Consortium, PRECISESADS Flow Cytometry, Elouej S, Duguet F, Laigle L, Poirier N, Moingeon P, Bretin S, Pers JO. High-Content Multimodal Analysis Supports the IL-7/IL-7 Receptor Axis as a Relevant Therapeutic Target in Primary Sjögren's Syndrome. See or download the preprint at SSRN.

The UMR1227 'B Lymphocytes and Autoimmunity' brings together several clinical entities around the immunology laboratory.

Rheumatology, haematology, nephorology and odontology for a scientific project articulated around two main complementary and interconnected axes: an axis dedicated to the understanding of the mechanisms that govern the functional orientation of B cells in autoimmunity, and a translational axis aiming at developing new tools to improve the efficiency of B-cell targeting immunotherapies, while working on a better stratification of patients, a better understanding of the mode of action of these therapies, and the development of these therapies and innovative therapeutic strategies.

They support us